Adenosine

• 

  Subject Areas on Research

  • 5' UTR m(6)A Promotes Cap-Independent Translation. 
  • A KINETIC INVESTIGATION OF THE INTERACTION OF ADENOSINE-5'-TRIPHOSPHATE WITH DIVALENT METAL IONS. 
  • A conserved bulged adenosine in a peripheral duplex of the antigenomic HDV self-cleaving RNA reduceskinetic trapping of inactive conformations. 
  • A critical reappraisal of aspirin for secondary prevention in patients with ischemic heart disease. 
  • A mathematical model of glutathione metabolism. 
  • A potentially abundant junctional RNA motif stabilized by m6A and Mg2. 
  • A randomized controlled trial of allopurinol vs. placebo added on to antipsychotics in patients with schizophrenia or schizoaffective disorder. 
  • A randomized trial to compare the safety of rivaroxaban vs aspirin in addition to either clopidogrel or ticagrelor in acute coronary syndrome: The design of the GEMINI-ACS-1 phase II study. 
  • A2a/D2 receptor interactions are not observed in COS-7 cells transiently transfected with dopamine D2 and adenosine A2a receptor cDNA. 
  • AZD6140. 
  • Acadesine inhibits neutrophil CD11b up-regulation in vitro and during in vivo cardiopulmonary bypass. 
  • Acute coronary syndrome antiplatelet alternatives in clopidogrel allergy. 
  • Acute termination of supraventricular tachycardia by adenosine during pregnancy. 
  • Addition of m6A to SV40 late mRNAs enhances viral structural gene expression and replication. 
  • Adenine and adenosine are toxic to human lymphoblast mutants defective in purine salvage enzymes. 
  • Adenosine A(3)-receptor stimulation attenuates postischemic dysfunction through K(ATP) channels. 
  • Adenosine as a non-opioid analgesic in the perioperative setting. 
  • Adenosine as an adjunct to thrombolytic therapy for acute myocardial infarction: results of a multicenter, randomized, placebo-controlled trial: the Acute Myocardial Infarction STudy of ADenosine (AMISTAD) trial. 
  • Adenosine for myocardial protection in acute myocardial infarction. 
  • Adenosine for temporary flow arrest during intracranial aneurysm surgery: a single-center retrospective review. 
  • Adenosine improves post-procedural coronary flow but not clinical outcomes in patients with acute coronary syndrome: a meta-analysis of randomized trials. 
  • Adenosine stress cardiac magnetic resonance imaging. 
  • Adenosine triphosphate activates ion permeabilities in biliary epithelial cells. 
  • Adenosine-induced flow arrest to facilitate intracranial aneurysm clip ligation does not worsen neurologic outcome. 
  • Adenosine-induced flow arrest to facilitate intracranial aneurysm clip ligation: dose-response data and safety profile. 
  • Adenosine-induced transient asystole for intracranial aneurysm surgery: a retrospective review. 
  • Advances in antiplatelet therapy: agents in clinical development. 
  • Aedes albopictus cells resistant to adenosine because of a defect in nucleoside transport. 
  • Alkaline Phosphatase, Soluble Extracellular Adenine Nucleotides, and Adenosine Production after Infant Cardiopulmonary Bypass. 
  • Analysis of myocardial function in orthotopic cardiac allografts after prolonged storage in UW solution. 
  • Antiangiogenic agents protect liver sinusoidal lining cells from cold preservation injury in rat liver transplantation. 
  • Antiplatelet and anticoagulation agents in acute coronary syndromes: what is the current status and what does the future hold? 
  • Antiplatelet therapy beyond 2012: role of personalized medicine. 
  • Antiplatelet treatment for prevention of cerebrovascular events in patients with vascular diseases: a systematic review and meta-analysis. 
  • Aspirin and clopidogrel resistance: consideration and management. 
  • Association Between Ischemic and Bleeding Risk Scores and the Use of New P2Y12 Inhibitors in Patients With Acute Coronary Syndrome. 
  • Balancing the risk of spontaneous ischemic and major bleeding events in acute coronary syndromes. 
  • Baseline Q waves as a prognostic modulator in patients with ST-segment elevation: insights from the PLATO trial. 
  • Basis for resistance to 3-deazaaristeromycin, an inhibitor of S-adenosylhomocysteine hydrolase, in human B-lymphoblasts. 
  • Bleeding complications with the P2Y12 receptor antagonists clopidogrel and ticagrelor in the PLATelet inhibition and patient Outcomes (PLATO) trial. 
  • Bronchospasm after intravenous adenosine administration. 
  • Calcium phosphate-bearing matrices induce osteogenic differentiation of stem cells through adenosine signaling. 
  • Cardiovascular events in acute coronary syndrome patients with peripheral arterial disease treated with ticagrelor compared with clopidogrel: Data from the PLATO Trial. 
  • Characterization of cardiac A1 adenosine receptors by ligand binding and photoaffinity labeling. 
  • Characterization of dyspnoea in PLATO study patients treated with ticagrelor or clopidogrel and its association with clinical outcomes. 
  • Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial. 
  • Cloning of the gene encoding Leishmania donovani S-adenosylhomocysteine hydrolase, a potential target for antiparasitic chemotherapy. 
  • Clopidogrel (Plavix) and cardiac surgical patients: implications for platelet function monitoring and postoperative bleeding. 
  • Combined immunodeficiency disease associated with adenosine deaminase deficiency. Report on a workshop held in Albany, New York, October 1, 1973. 
  • Common actions of adenosine receptor agonists in modulating human trabecular meshwork cell transport. 
  • Comparison of postoperative pain outcomes after vertical or Pfannenstiel incision for major gynecologic surgery. 
  • Comparison of the prognostic value of regadenoson and adenosine myocardial perfusion imaging. 
  • Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind study. 
  • Comparison of ticagrelor, the first reversible oral P2Y(12) receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial. 
  • Comprehensive analysis of mRNA methylation reveals enrichment in 3' UTRs and near stop codons. 
  • Correlation of adenosine echocardiography and thallium scintigraphy. 
  • Correlation of intrinsic optical signal, cerebral blood flow, and evoked potentials during activation of rat somatosensory cortex. 
  • Covalent labelling of ligand binding sites of human placental S-adenosylhomocysteine hydrolase with 8-azido derivatives of adenosine and cyclic AMP. 
  • Crystal structures of Toxoplasma gondii adenosine kinase reveal a novel catalytic mechanism and prodrug binding. 
  • Crystal structures of Toxoplasma gondii adenosine kinase reveal a novel catalytic mechanism and prodrug binding. 
  • Current controversies in the use of aspirin and ticagrelor for the treatment of thrombotic events. 
  • Cystatin C and estimated glomerular filtration rate as predictors for adverse outcome in patients with ST-elevation and non-ST-elevation acute coronary syndromes: results from the Platelet Inhibition and Patient Outcomes study. 
  • Cytotoxic and metabolic effects of adenosine and adenine on human lymphoblasts. 
  • Design and rationale for the Effects of Ticagrelor and Clopidogrel in Patients with Peripheral Artery Disease (EUCLID) trial. 
  • Determination of extent and location of coronary artery disease in patients without prior myocardial infarction by thallium-201 tomography with pharmacologic stress. 
  • Dexmedetomidine: therapeutic use for the termination of reentrant supraventricular tachycardia. 
  • Direct Conversion of Human Pluripotent Stem Cells to Osteoblasts With a Small Molecule. 
  • Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation. 
  • Earlier recovery of platelet function after discontinuation of treatment with ticagrelor compared with clopidogrel in patients with high antiplatelet responses. 
  • Economic analysis of ticagrelor therapy from a U.S. perspective: results from the PLATO study. 
  • Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial. 
  • Effect of adenosine on transmural myocardial blood flow distribution in the awake dog. 
  • Effect of adenosine-regulating agent acadesine on morbidity and mortality associated with coronary artery bypass grafting: the RED-CABG randomized controlled trial. 
  • Effect of alpha-isopropylmalate on the synthesis of RNA and protein in Neurospora. 
  • Effect of atrial fibrillation on atrial blood flow in conscious dogs. 
  • Effect of genetic variations on ticagrelor plasma levels and clinical outcomes. 
  • Effects of dose ranging of adenosine infusion on electrocardiographic findings during and after general anesthesia. 
  • Effects of increased myocardial oxygen consumption on coronary reactive hyperemia in the awake dog. 
  • Efficiency comparison between 99m Tc-tetrofosmin and 99m Tc-sestamibi myocardial perfusion studies. 
  • Electrocardiographic infarct size assessment after thrombolysis: insights from the Acute Myocardial Infarction STudy ADenosine (AMISTAD) trial. 
  • Endogenous adenosine produced during hypoxia attenuates neutrophil accumulation: coordination by extracellular nucleotide metabolism. 
  • Endogenous production of extracellular adenosine by trabecular meshwork cells: potential role in outflow regulation. 
  • Enhanced cardiac preservation with oxygenated University of Wisconsin solution. 
  • Evaluation of ischemic heart disease. 
  • Evaluation of solutions for small intestinal preservation. Biochemical changes as a function of storage time. 
  • Examining biology and pharmacology-based hypotheses in the PLATO trial. 
  • Experience with combined hepatic, pancreaticoduodenal, and renal procurement with UW solution. 
  • Explaining the unexpected: insights from the PLATelet inhibition and clinical Outcomes (PLATO) trial comparing ticagrelor and clopidogrel. Editorial on Serebruany "Viewpoint: Paradoxical excess mortality in the PLATO trial should be independently verified" (Thromb Haemost 2011; 105.5). 
  • Factors contributing to the lower mortality with ticagrelor compared with clopidogrel in patients undergoing coronary artery bypass surgery. 
  • First analysis of the relation between CYP2C19 genotype and pharmacodynamics in patients treated with ticagrelor versus clopidogrel: the ONSET/OFFSET and RESPOND genotype studies. 
  • Group I intron self-splicing with adenosine: evidence for a single nucleoside-binding site. 
  • HIF-1-dependent repression of equilibrative nucleoside transporter (ENT) in hypoxia. 
  • Heterologous desensitization of the inhibitory A1 adenosine receptor-adenylate cyclase system in rat adipocytes. Regulation of both Ns and Ni. 
  • High-dose, but not low-dose, aspirin impairs anticontractile effect of ticagrelor following ADP stimulation in rat tail artery smooth muscle cells. 
  • High-threshold Ca2+ currents in rat hippocampal interneurones and their selective inhibition by activation of GABA(B) receptors. 
  • Hormone-sensitive adenylate cyclase. Delineation of a trypsin-sensitive site in the pathway of receptor-mediated inhibition. 
  • How country-specific should a country-specific cost-effectiveness analysis be? 
  • Human genetic and metabolite variation reveals that methylthioadenosine is a prognostic biomarker and an inflammatory regulator in sepsis. 
  • Identification and biochemical studies on novel non-nucleoside inhibitors of the enzyme adenosine kinase. 
  • Immune-related intestinal chloride secretion. II. Effect of adenosine on T84 cell line. 
  • Impact of donor factors and preservation on function and survival after liver transplantation. 
  • Impact of glycoprotein IIb/IIIa inhibitors on the efficacy and safety of ticagrelor compared with clopidogrel in patients with acute coronary syndromes: Analysis from the Platelet Inhibition and Patient Outcomes (PLATO) Trial. 
  • Impact of morphine on antiplatelet effects of oral P2Y12 receptor inhibitors. 
  • In-hospital switching between adenosine diphosphate receptor inhibitors in patients with acute myocardial infarction treated with percutaneous coronary intervention: Insights into contemporary practice from the TRANSLATE-ACS study. 
  • Incidence of dyspnea and assessment of cardiac and pulmonary function in patients with stable coronary artery disease receiving ticagrelor, clopidogrel, or placebo in the ONSET/OFFSET study. 
  • Incremental prognostic value of RNA ejection fraction measurements during pharmacologic stress testing: a comparison with clinical and perfusion variables. 
  • Influence of Zaprinast on vascular tone and vasodilator responses in the cat pulmonary vascular bed. 
  • Influence of genetic polymorphisms on platelet function, response to antiplatelet drugs and clinical outcomes in patients with coronary artery disease. 
  • Inhibition of adenosine-1 receptor-mediated preglomerular vasoconstriction in AT1A receptor-deficient mice. 
  • Inhibition of tumor necrosis factor release from cultured rat Kupffer cells by agents that reduce graft failure from storage injury. 
  • Inhibitory effects of ticagrelor compared with clopidogrel on platelet function in patients with acute coronary syndromes: the PLATO (PLATelet inhibition and patient Outcomes) PLATELET substudy. 
  • Intestinal transplantation: the University of Wisconsin experience. 
  • Intravenous adenosine selectively increases blood flow to xenotransplanted intracerebral gliomas. 
  • Letter by Grbel et al regarding article, "administration of a loading dose has no additive effect on platelet aggregation during the switch from ongoing clopidogrel treatment to ticagrelor in patients with acute coronary syndrome". 
  • Letter by Moris et al Regarding Article, "Ticagrelor in Acute Stroke or Transient Ischemic Attack in Asian Patients: From the SOCRATES Trial (Acute Stroke or Transient Ischemic Attack Treated With Aspirin or Ticagrelor and Patient Outcomes)". 
  • Lifetime cost-effectiveness analysis of ticagrelor in patients with acute coronary syndromes based on the PLATO trial: a Singapore healthcare perspective. 
  • Long-Term Use of Ticagrelor in Patients with Prior Myocardial Infarction. 
  • Longitudinal treatment patterns with ADP receptor inhibitors after myocardial infarction: Insights from the Canadian Observational AntiPlatelet sTudy. 
  • Mechanisms of ATP release by human trabecular meshwork cells, the enabling step in purinergic regulation of aqueous humor outflow. 
  • Meta-analysis of direct and indirect comparison of ticagrelor and prasugrel effects on platelet reactivity. 
  • Metabolic mediation of single brief diastolic occlusion reactive hyperemic responses. 
  • Methylthioadenosine Suppresses Salmonella Virulence. 
  • Molecular form of adenosine deaminase in severe combined immunodeficiency. 
  • More Evidence for Non-P2Y12-Mediated Effects of Ticagrelor. 
  • Multiple roles for the active zone protein RIM1alpha in late stages of neurotransmitter release. 
  • Myocardial blood flow in awake dogs with chronic tricuspid regurgitation. 
  • Myocardial uptake and clearance of T1-201 in healthy subjects: comparison of adenosine-induced hyperemia and exercise stress. 
  • N6-Methyladenosine in Flaviviridae Viral RNA Genomes Regulates Infection. 
  • N6-methyladenosine is required for the hypoxic stabilization of specific mRNAs. 
  • N6-methyladenosine modification of hepatitis B virus RNA differentially regulates the viral life cycle. 
  • N6-phenyladenosines: pronounced effect of phenyl substituents on affinity for A2 adenosine receptors. 
  • New insights into adenosine-receptor-mediated immunosuppression and the role of adenosine in causing the immunodeficiency associated with adenosine deaminase deficiency. 
  • Nicotinamide adenine dinucleotide (NAD) and its metabolites inhibit T lymphocyte proliferation: role of cell surface NAD glycohydrolase and pyrophosphatase activities. 
  • Novel antiplatelet agent ticagrelor in the management of acute coronary syndrome. 
  • Optimal P2Y12 Inhibitor in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention: A Network Meta-Analysis. 
  • Optimizing platelet P2Y12 inhibition for patients undergoing PCI. 
  • Outcome and causes of renal deterioration evaluated by serial cystatin C measurements in acute coronary syndrome patients -- results from the PLATelet inhibition and patient Outcomes (PLATO) study. 
  • Outcome prediction in patients at high risk for coronary artery disease: comparison between 99mTc tetrofosmin and 99mTc sestamibi. 
  • Outcomes of Patients with Critical Limb Ischaemia in the EUCLID Trial. 
  • P2Y12 Receptor Blockade and Myocardial Perfusion. 
  • Paroxysmal high-grade atrioventricular block and syncope in a previously healthy child: what is the mechanism? 
  • Perioperative cardiac complications and 30-day mortality in patients undergoing intracranial aneurysmal surgery with adenosine-induced flow arrest: a retrospective comparative study. 
  • Perturbations in S-adenosylhomocysteine and S-adenosylmethionine metabolism: effects on transmethylation. 
  • Pharmacodynamic evaluation of switching from ticagrelor to prasugrel in patients with stable coronary artery disease: Results of the SWAP-2 Study (Switching Anti Platelet-2). 
  • Pharmacokinetics and pharmacodynamics of ticagrelor in patients with stable coronary artery disease: results from the ONSET-OFFSET and RESPOND studies. 
  • Pharmacologic disruption of Polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells. 
  • Phase 2, double-blind, placebo-controlled, dose-response trial of intravenous adenosine for perioperative analgesia. 
  • Phenotypic dissections of the Blastocladiella emersonii zoospore's developmental choice. 
  • Phorbol esters enhance neurotransmitter-stimulated cyclic AMP production in rat brain slices. 
  • Platelet reactivity during ticagrelor maintenance therapy: a patient-level data meta-analysis. 
  • Platelet-related biomarkers and their response to inhibition with aspirin and p2y12-receptor antagonists in patients with acute coronary syndrome. 
  • Poststress measurements of left ventricular function with gated perfusion SPECT: comparison with resting measurements by using a same-day perfusion-function protocol. 
  • Preparation, biological activity and endogenous occurrence of N6-benzyladenosines. 
  • Prior smoking status, clinical outcomes, and the comparison of ticagrelor with clopidogrel in acute coronary syndromes-insights from the PLATelet inhibition and patient Outcomes (PLATO) trial. 
  • Procurement, preservation, and transport of cadaver kidneys. 
  • Prognostic value of normal exercise and adenosine (99m)Tc-tetrofosmin SPECT imaging: results from the multicenter registry of 4,728 patients. 
  • Pseudouridine and N6-methyladenosine modifications weaken PUF protein/RNA interactions. 
  • Pulmonary edema post-cardioversion: a potential calcium signalling problem. 
  • Pulmonary function in patients with acute coronary syndrome treated with ticagrelor or clopidogrel (from the Platelet Inhibition and Patient Outcomes [PLATO] pulmonary function substudy). 
  • Purine nucleotides contribute to pulmonary vasodilation caused by birth-related stimuli in the ovine fetus. 
  • Purine synthesis and excretion in mutants of the WI-L2 human lymphoblastoid line deficient in adenosine kinase (AK) and adenine phosphoribosyltransferase (APRT). 
  • Purine toxicity in human lymphoblasts. 
  • Quantitative ST-depression in acute coronary syndromes: the PLATO electrocardiographic substudy. 
  • RNA modifications go viral. 
  • Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study. 
  • Rationale and design of the Affordability and Real-world Antiplatelet Treatment Effectiveness after Myocardial Infarction Study (ARTEMIS): A multicenter, cluster-randomized trial of P2Y12 receptor inhibitor copayment reduction after myocardial infarction. 
  • Re-design of Rhodobacter sphaeroides dimethyl sulfoxide reductase. Enhancement of adenosine N1-oxide reductase activity. 
  • Regional myocardial blood flow in awake dogs. 
  • Regional vascular reserve in canine atria and ventricles during rest and exercise. 
  • Regulation of glutamate and aspartate release from slices of the hippocampal CA1 area: effects of adenosine and baclofen. 
  • Regulation of glutamate and aspartate release from the Schaffer collaterals and other projections of CA3 hippocampal pyramidal cells. 
  • Requirements for T lymphocyte migration in explanted lymph nodes. 
  • Response to letter regarding article, "Ticagrelor in patients with acute coronary syndromes and stroke: interpretation of subgroups in clinical trials". 
  • Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies: the RESPOND study. 
  • Rethinking m6A Readers, Writers, and Erasers. 
  • Review of the accumulated PLATO documentation supports reliable and consistent superiority of ticagrelor over clopidogrel in patients with acute coronary syndrome: Commentary on: DiNicolantonio JJ, Tomek A, Inactivations, deletions, non-adjudications, and downgrades of clinical endpoints on ticagrelor: serious concerns over the reliability of the PLATO trial, International Journal of Cardiology, 2013. 
  • Role of mitochondrial aldehyde dehydrogenase in nitroglycerin-induced vasodilation of coronary and systemic vessels: an intact canine model. 
  • Role of transmethylation reactions in cellular motility and phagocytosis. 
  • S-Adenosylhomocysteine hydrolase from human placenta. Affinity purification and characterization. 
  • S-Adenosylhomocysteine metabolism in adenosine deaminase deficient cells. 
  • S-adenosylhomocysteine catabolism and basis for acquired resistance during treatment of T-cell acute lymphoblastic leukemia with 2'-deoxycoformycin alone and in combination with 9-beta-D-arabinofuranosyladenine. 
  • S-adenosylhomocysteine hydrolase is an adenosine-binding protein: a target for adenosine toxicity. 
  • S-adenosylhomocysteine toxicity in normal and adenosine kinase-deficient lymphoblasts of human origin. 
  • ST-elevation acute coronary syndromes in the Platelet Inhibition and Patient Outcomes (PLATO) trial: insights from the ECG substudy. 
  • Safety and Ergogenic Properties of Combined Aminophylline and Ambrisentan in Hypoxia. 
  • Safety and efficacy of ticagrelor and clopidogrel in primary percutaneous coronary intervention. 
  • Small molecule-driven direct conversion of human pluripotent stem cells into functional osteoblasts. 
  • Specific photoaffinity labelling of inhibitory adenosine receptors. 
  • Spinophilin blocks arrestin actions in vitro and in vivo at G protein-coupled receptors. 
  • Stimulus-specific effects of pentoxifylline on neutrophil CR3 expression, degranulation, and superoxide production. 
  • Structural mapping of rabbit muscle phosphofructokinase. Distance between the adenosine cyclic 3',5'-phosphate binding site and a reactive sulfhydryl group. 
  • Structure of the N-terminal domain of GRP94. Basis for ligand specificity and regulation. 
  • Suppression of lipopolysaccharide-stimulated release of tumor necrosis factor by adenosine: evidence for A2 receptors on rat Kupffer cells. 
  • Switching of adenosine diphosphate receptor inhibitor after hospital discharge among myocardial infarction patients: Insights from the Treatment with Adenosine Diphosphate Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events after Acute Coronary Syndrome (TRANSLATE-ACS) observational study. 
  • TP53 genomic status regulates sensitivity of gastric cancer cells to the histone methylation inhibitor 3-deazaneplanocin A (DZNep). 
  • Termination of paroxysmal supraventricular tachycardia by tecadenoson (CVT-510), a novel A1-adenosine receptor agonist. 
  • Thallium-201 myocardial imaging in patients with coronary artery disease: comparison of intravenous adenosine and oral dipyridamole. 
  • The Dogged Search for Cryptic Effects of Ticagrelor: Wishful Thinking or Real Benefits Beyond P2Y12 Inhibition? 
  • The GS Protein-coupled A2a Adenosine Receptor Controls T Cell Help in the Germinal Center. 
  • The PARTHENON Clinical Development Program: the Role of Ticagrelor in Patients with Atherothrombotic Disease. 
  • The PLATO trial reveals further opportunities to improve outcomes in patients with acute coronary syndrome. Editorial on Serebruany. "Viewpoint: Paradoxical excess mortality in the PLATO trial should be independently verified" (Thromb Haemost 2011; 105.5). 
  • The birth of the Epitranscriptome: deciphering the function of RNA modifications. 
  • The coronary pressure-flow determinants left ventricular compliance in dogs. 
  • The dynamic epitranscriptome: N6-methyladenosine and gene expression control. 
  • The effect of ticagrelor versus clopidogrel on high on-treatment platelet reactivity: combined analysis of the ONSET/OFFSET and RESPOND studies. 
  • The efficacy of ticagrelor is maintained in women with acute coronary syndromes participating in the prospective, randomized, PLATelet inhibition and patient Outcomes (PLATO) trial. 
  • The power of more than one. 
  • The predictive value of donor liver biopsies on the development of primary nonfunction after orthotopic liver transplantation. 
  • The rat testicular A1 adenosine receptor-adenylate cyclase system. 
  • The use of UW solution in clinical transplantation. A 4-year experience. 
  • The use of adenosine in the treatment of a high-flow vein of Galen malformation in an adult. 
  • The use of enzyme therapy to regulate the metabolic and phenotypic consequences of adenosine deaminase deficiency in mice. Differential impact on pulmonary and immunologic abnormalities. 
  • The use of tomographic myocardial perfusion scanning to evaluate an electrocardiographic salvage estimation method in patients with acute myocardial infarction: an AMISTAD substudy. Acute Myocardial Infarction Study Adenosine. 
  • Ticagrelor Compared With Clopidogrel in Patients With Prior Lower Extremity Revascularization for Peripheral Artery Disease. 
  • Ticagrelor Following Coronary Artery Bypass Grafting: For Better Vein Graft Patency or Better Patient Outcomes? 
  • Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial. 
  • Ticagrelor effects on myocardial infarction and the impact of event adjudication in the PLATO (Platelet Inhibition and Patient Outcomes) trial. 
  • Ticagrelor for the treatment of arterial thrombosis. 
  • Ticagrelor in patients with acute coronary syndromes and stroke: interpretation of subgroups in clinical trials. 
  • Ticagrelor versus Clopidogrel in Peripheral Artery Disease. 
  • Ticagrelor versus Clopidogrel in Symptomatic Peripheral Artery Disease. 
  • Ticagrelor versus clopidogrel in elderly patients with acute coronary syndromes: a substudy from the prospective randomized PLATelet inhibition and patient Outcomes (PLATO) trial. 
  • Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention: A Platelet Inhibition and Patient Outcomes (PLATO) trial subgroup analysis. 
  • Ticagrelor versus clopidogrel in patients with acute coronary syndromes and a history of stroke or transient ischemic attack. 
  • Ticagrelor versus clopidogrel in patients with acute coronary syndromes intended for non-invasive management: substudy from prospective randomised PLATelet inhibition and patient Outcomes (PLATO) trial. 
  • Ticagrelor versus clopidogrel in patients with acute coronary syndromes undergoing coronary artery bypass surgery: results from the PLATO (Platelet Inhibition and Patient Outcomes) trial. 
  • Ticagrelor versus clopidogrel in patients with acute coronary syndromes. 
  • Ticagrelor with aspirin or alone in high-risk patients after coronary intervention: Rationale and design of the TWILIGHT study. 
  • Trabodenoson, an Adenosine Mimetic With A1 Receptor Selectivity Lowers Intraocular Pressure by Increasing Conventional Outflow Facility in Mice. 
  • Transient adenosine-induced asystole during the surgical treatment of anterior circulation cerebral aneurysms: technical note. 
  • Transmethylation reactions are required for initial morphologic and biochemical responses of human monocytes to chemoattractants. 
  • Transmethylation reactions regulate affinity and functional activity of chemotactic factor receptors on macrophages. 
  • Triphenyl phosphite-induced ultrastructural changes in bovine adrenomedullary chromaffin cells. 
  • Understanding the Adverse Effects of Ticagrelor in Practice. 
  • Unexpected Cardiac MRI Findings in Patients Presenting to the Emergency Department for Possible Acute Coronary Syndrome. 
  • Unravelling the smokers' paradox: cigarette smoking, high-risk coronary artery disease and enhanced clinical efficacy of oral P2Y₁₂ inhibitors. 
  • Update on preservation of liver grafts. 
  • Use of multiple radioligands to characterize adenosine receptors in human placenta. 
  • Usefulness of the VerifyNow P2Y12 assay to evaluate the antiplatelet effects of ticagrelor and clopidogrel therapies. 
  • Utilization of pediatric donors for pancreas transplantation. 
  • Value of cardiovascular magnetic resonance stress perfusion testing for the detection of coronary artery disease in women. 
  • Vasoactive drugs produce selective changes in flow to experimental brain tumors. 
  • Viral Epitranscriptomics. 
  • m(1)A and m(1)G disrupt A-RNA structure through the intrinsic instability of Hoogsteen base pairs. 
• 

  Keywords of People

  • Granger, Christopher Bull, Professor of Medicine, School of Nursing
  • MacLeod, Amanda S, Associate Professor in Dermatology, Immunology